Want to see TSE:HBP full AI Analyst Report?
Top Page
Helix BioPharma
(TSX:HBP)
Select Model
Select Model
Rating:52Neutral
Price Target:
C$2.00
▲(0.50% Upside)
Action:Reiterated
Date:08/26/26
The score is held back primarily by pre-revenue financials with ongoing losses and cash burn, partially offset by a strengthened balance sheet with low leverage. Technicals are supportive (uptrend) but appear overextended, while valuation remains weak due to negative earnings. Recent positive corporate events modestly improve the outlook on execution.
Positive Factors
Low leverage and improved equity
Very low debt relative to equity reduces solvency pressure, while the shift from negative to positive equity improves financial stability. This provides a stronger balance-sheet base for funding clinical development than in earlier periods.
Negative Factors
No recurring revenue
Without product or licensing revenue, Helix lacks an operating base to absorb fixed costs and support development internally. Persistent losses leave future value dependent on clinical progress and eventual monetization of drug candidates.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and improved equity
Very low debt relative to equity reduces solvency pressure, while the shift from negative to positive equity improves financial stability. This provides a stronger balance-sheet base for funding clinical development than in earlier periods.
Read all positive factors
Helix BioPharma (HBP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$137.48M
Dividend YieldN/A
Average Volume (3M)2.30K
Price to Earnings (P/E)―
Beta (1Y)2.34
Revenue GrowthN/A
EPS Growth77.30%
CountryCA
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding76,378,100
10 Day Avg. Volume2,583
30 Day Avg. Volume2,296
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Helix BioPharma Business Overview & Revenue Model
Company Description
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets t...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Helix BioPharma’s operations have typically not been driven by recurring product sales; instead, its funding and potential revenue sources generally come from capital raising (e.g., equity financings)...
Helix BioPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.00K | -10.00K | -14.00K | -13.00K | -12.00K | -173.00K |
| EBITDA | -3.08M | -5.21M | -9.38M | -6.31M | -6.03M | -9.46M |
| Net Income | -3.32M | -5.21M | -9.26M | -6.29M | -6.08M | -7.91M |
Balance Sheet | ||||||
| Total Assets | 21.38M | 18.80M | 1.49M | 1.03M | 3.73M | 4.07M |
| Cash, Cash Equivalents and Short-Term Investments | 2.84M | 65.00K | 1.08M | 808.00K | 3.25M | 3.56M |
| Total Debt | 359.00K | 336.00K | 0.00 | 0.00 | 2.47M | 3.61M |
| Total Liabilities | 6.69M | 3.22M | 1.58M | 1.87M | 3.41M | 5.46M |
| Stockholders Equity | 14.69M | 15.59M | -90.00K | -844.00K | 319.00K | -1.39M |
Cash Flow | ||||||
| Free Cash Flow | -3.21M | -3.83M | -5.23M | -5.54M | -6.51M | -9.30M |
| Operating Cash Flow | -3.21M | -3.83M | -5.22M | -5.53M | -6.51M | -9.30M |
| Investing Cash Flow | 0.00 | 17.00K | -14.00K | -5.00K | 0.00 | 2.02M |
| Financing Cash Flow | 5.32M | 2.80M | 5.51M | 3.09M | 6.21M | 6.56M |
Helix BioPharma Technical Analysis
Negative
1.99
Price Trends
1.64
Negative
1.65
Negative
1.85
Negative
Market Momentum
0.04
Positive
40.93
Neutral
24.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HBP, the sentiment is Negative. The current price of 1.99 is above the 20-day moving average (MA) of 1.90, above the 50-day MA of 1.64, and above the 200-day MA of 1.85, indicating a bearish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 40.93 is Neutral, neither overbought nor oversold. The STOCH value of 24.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HBP.
Helix BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$137.48M | -37.05 | -21.54% | ― | ― | 77.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$270.93M | -5.12 | -71.28% | ― | ― | -6.00% | |
46 Neutral | C$35.70M | -1.95 | -360.29% | ― | ― | -33.27% | |
44 Neutral | C$65.22M | -22.59 | 74.79% | ― | ― | -15.53% |
* Healthcare Sector Average
TSE:HBP
Helix BioPharma
1.63
0.13
8.67%
TSE:MSCL
Satellos Bioscience
13.85
5.69
69.73%
TSE:ARCH
Arch Biopartners
0.96
-0.68
-41.46%
TSE:MDNA
Medicenna Therapeutics Corp
0.43
-0.61
-58.65%
TSE:METX
ME Therapeutics Holdings, Inc.
2.25
-2.15
-48.86%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Helix BioPharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Helix BioPharma Taps Veteran Oncologist Markus Loeffler as CMO for Next Clinical Phase
Positive
Aug 17, 2026
Helix BioPharma Corp. is a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, with a focus on underserved patient populations. Its pipeline is led by L-DOS47, an antibody-enzyme conjugate being advanced as a...
Business Operations and StrategyExecutive/Board Changes
Helix BioPharma Reshapes Board to Align with Oncology Growth Strategy
Positive
Aug 14, 2026
Helix BioPharma Corp., a Vancouver-based clinical-stage oncology firm developing novel cancer therapies, has adjusted its board composition following its recent strategic expansion of pipeline assets. The move comes as the company continues to adv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.